Source link : https://newshealth.biz/health-news/fda-advisory-panel-votes-no-on-belantamab-for-myeloma/
A bid by GlaxoSmithKline (GSK) to bring its multiple myeloma drug belantamab mafodotin (Blenrep) back to the market hit a stumbling block during an US FDA panel meeting held on July 17. The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 5-3 against belantamab in combination with bortezomib and dexamethasone and 7-1 against belantamab in combination […]
The post FDA Advisory Panel Votes NO on Belantamab for Myeloma first appeared on News Health.
—-
Author : News Health
Publish date : 2025-07-21 05:50:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8